Other Events ·
SCYNEXIS, Inc. stockholders at the June 25, 2026 Annual Meeting approved an amendment to its Certificate of…
SCYXScynexis Inc
SCYNEXIS, Inc. stockholders at the June 25, 2026 Annual Meeting approved an amendment to its Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 60,000,000 shares (pre-reverse stock split). The company also filed a Registration Statement on Form S-3 to register the resale of up to 87,000,000 shares of Common Stock, including shares held by selling stockholders and shares issuable upon the exercise of pre-funded and common warrants. SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing specialty antibiotic treatments.